Expert Agreement on EULAR/EUSTAR Recommendations for the Management of Systemic Sclerosis

REFERENCES

1. 1.↵
   1. Kowal-Bielecka O,
   2. Landewé R,
   3. Avouac J,
   4. Chwiesko S,
   5. Miniati I,
   6. Czirjak L,
   7. et al.

   EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620–8.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Cabana MD,
   2. Rand CS,
   3. Powe NR

   . Why don’t physicians follow clinical practice guidelines?: A framework for improvement. JAMA 1999;282:1458–65.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Pope JE,
   2. Bellamy N,
   3. Seibold JR,
   4. Baron M,
   5. Ellman M,
   6. Carette S,
   7. et al.

   A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2004;44:1351–8.

   OpenUrl
4. 4.↵
   1. van den Hoogen FH,
   2. Boerbooms AM,
   3. Swaak AJ,
   4. Rasker JJ,
   5. van Lier HJ,
   6. van de Putte LB

   . Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24-week observational trial. Br J Rheumatol 1996;35:364–72.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Korn J,
   2. Mayes M,
   3. Matucci-Cerinic M,
   4. Rainisio M,
   5. Rainisio M,
   6. Pope J,
   7. et al.

   Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985–93.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Matucci-Cerinic M,
   2. Denton CP,
   3. Furst DE,
   4. Mayes MD,
   5. Hsu VM,
   6. Carpentier P,
   7. et al.

   Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70:32–8.

   OpenUrlAbstract/FREE Full Text